News

Real-world data show ruxolitinib cream improves facial vitiligo in 3 months, boosting quality of life and imaging-confirmed repigmentation.

New trials show oral psoriasis drugs rival biologics, expand care across ages, and spotlight systemic risks—plus the ongoing fight for access. Read our exclusive recap for PsO Action Month.

The investigational anti–IL-13 monoclonal antibody could change how dermatologists think about biologic dosing in moderate to severe AD.

Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are exosome-derived products legitimate or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Split-face trial finds 34-gauge low-dead-space injector makes upper-face Botox injections hurt less, bruise less, and waste fewer units.

FDA clears RHA Redensity Eye for undereye hollows, offering soft, stretchable HA filler with 12-month results and strong safety data in a 52-week study.

Learn how private equity rollups reshape dermatology—EBITDA deals, MSOs, and the real tradeoffs for owners, PAs, and new grads.

Heather Woolery-Lloyd, MD, reviews a new clinical study quantifying linear hair growth rate across 4 Nutrafol formulations.

Shanna Miranti, MPAS, PA-C, explores how fertility treatments can affect skin and hair, including acne, melasma, and hair loss, and offers guidance for patient care.

In the new episode of Don't Be Rash, learn why early pulsed dye laser helps pediatric PWCMs, what drives recurrence, and which new therapies may boost results.

Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.

Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.

MotherToBaby launched a pregnancy study to address limited safety data for lebrikizumab use in patients with atopic dermatitis.

Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.

Phase 3 data from Merck and Moderna show mRNA vaccine intismeran plus pembrolizumab cuts melanoma relapse and spread after surgery, hinting at new adjuvant standard.

Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.

New research shows dermatologists continue to back daily sunscreen to prevent aging and skin cancer, debunking viral myths and spotlighting safer new filters coming to the US.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

Alexandra Richmond, MD, explains realistic hair-loss timelines, scarring alopecia limits, combination therapies, PRP and supplements, plus promising insights on extended‑release oral minoxidil.

Tattoo science goes skin deep, from ink placement and healing to adverse reactions, aftercare, and the dermatologic effects of pigment.

This review of the latest dermatological studies includes insights on brodalumab for plaque psoriasis, physiological characteristics of scalps with high sebum production, disease burden of anogenital PsO, and more.

Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.

Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.

Judson Brewer, MD, PhD, discussed how the trigger-behavior-result habit loop model can be applied to itch-scratch cycles in atopic dermatitis.

GBD 2021 shows urticaria burden in the Middle East and North Africa has stayed flat for 3 decades, but rates vary widely based on location, gender, age, and more.

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.

In the August letter from the editor in chief, Christopher Bunick, MD, PhD, explains bemotrizinol’s broad-spectrum UVA/UVB benefits and simple UV safety habits for sunscreen, pools, and wounds.

Social media skin care trends drive excess product use, skin barrier damage, delayed dermatologist visits, and worse acne—especially among TikTok and influencer-following users.